Available clinical trials for Alzheimer’s disease

This study reviews a new treatment to prevent memory decline and slow the earliest symptoms of Alzheimer’s disease.

Eligibility: Adults ages 55 to 80 with a reliable study partner to provide information; adults ages 55-64 must have a listed risk factor

A new approach to dementia treatment- targeting the proteins connected to memory loss.
Patients will receive 3TC, an FDA-approved drug commonly prescribed for HIV and Hepatitis B.
Research shows that 3TC slows the disease mechanisms present in the early phases of Alzheimer’s disease.

Eligibility: Adults, 50 to 80 years, diagnosed with Alzheimer’s disease

The REACH clinical trial is 1 of 16 trials worldwide offering promising therapies for Alzheimer’s disease and dementia funded by the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates.
The trial will evaluate the use of Rapamycin to slow progression of amnestic mild cognitive impairment and early-stage Alzheimer’s. It will also collect vital information on Alzheimer’s markers and relevant outcomes for future clinical trials.

Eligibility: Adults, ages 55 to 89, diagnosed with mild cognitive impairment or Alzheimer’s disease

The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.

Eligibility: Adults, ages 55 to 85, diagnosed with mild cognitive impairment or early stages of Alzheimer’s disease

The purpose of this study is to evaluate if a combination of two medications may be an effective intervention for treating AD symptoms in future studies.

Eligibility: Adults, aged 65 years or older, with a diagnosis of Alzheimer’s disease